Related Experiment Video
Updated: Jul 13, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Defining the role of mTOR in cancer
David A Guertin1, David M Sabatini
1Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology, Department of Biology, Cambridge, MA 02141, USA.
Abstract:
The mammalian target of rapamycin (mTOR) has emerged as a critical effector in cell-signaling pathways commonly deregulated in human cancers. This has led to the prediction that mTOR inhibitors may be useful in oncology, and derivatives of one such molecule, rapamycin (from which mTOR derives its name), are currently in clinical development. In this review, we discuss recent progress in understanding mTOR signaling, paying particular attention to its relevance in cancer. We further discuss the use of rapamycin in oncology and conclude with a discussion on the future of mTOR-targeted therapy.
Insights
Mammalian target of rapamycin (mTOR) pathway deregulation is common in human cancers. mTOR inhibitors, like rapamycin, show promise for targeted cancer therapy and are in clinical development.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- The mammalian target of rapamycin (mTOR) pathway is frequently dysregulated in human cancers.
- mTOR signaling plays a critical role in cell growth, proliferation, and survival, making it a key target in cancer development.
Purpose of the Study:
- To review recent advancements in understanding mTOR signaling pathways.
- To highlight the relevance of mTOR signaling in the context of human cancers.
- To discuss the therapeutic potential of mTOR inhibitors, particularly rapamycin, in oncology.
Main Methods:
- Literature review of recent scientific publications.
- Analysis of studies focusing on mTOR signaling pathways.
- Examination of clinical data regarding mTOR inhibitors in cancer treatment.
Main Results:
- mTOR signaling is a central pathway implicated in various human malignancies.
- Rapamycin and its derivatives are under active clinical investigation as anti-cancer agents.
- Understanding mTOR signaling provides a basis for developing novel targeted therapies.
Conclusions:
- mTOR pathway dysregulation is a significant hallmark of cancer.
- mTOR inhibitors, including rapamycin, represent a promising therapeutic strategy for cancer treatment.
- Future research should focus on optimizing mTOR-targeted therapies for improved patient outcomes.
More Related Videos
11:13Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
09:37A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Mitogens and the Cell Cycle
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...